Nanobac Pharmaceuticals Incorporated Stock Probability of Future Stock Price Finishing Over 1.0E-4

NNBP Stock  USD 0.0001  0.00  0.00%   
Nanobac Pharmaceuticals' future price is the expected price of Nanobac Pharmaceuticals instrument. It is based on its current growth rate as well as the projected cash flow expected by the investors. This tool provides a mechanism to make assumptions about the upside potential and downside risk of Nanobac Pharmaceuticals Incorporated performance during a given time horizon utilizing its historical volatility. Check out Nanobac Pharmaceuticals Backtesting, Nanobac Pharmaceuticals Valuation, Nanobac Pharmaceuticals Correlation, Nanobac Pharmaceuticals Hype Analysis, Nanobac Pharmaceuticals Volatility, Nanobac Pharmaceuticals History as well as Nanobac Pharmaceuticals Performance.
  
As of 12/02/2024, Price To Sales Ratio is likely to drop to 90.90. In addition to that, Price Earnings Ratio is likely to drop to -5.81. Please specify Nanobac Pharmaceuticals' target price for which you would like Nanobac Pharmaceuticals odds to be computed.

Nanobac Pharmaceuticals Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Nanobac Pharmaceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Nanobac Pharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Nanobac Pharmaceuticals generated a negative expected return over the last 90 days
Nanobac Pharmaceuticals has some characteristics of a very speculative penny stock
Nanobac Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years
The company reported the previous year's revenue of 17.62 K. Net Loss for the year was (6.58 M) with profit before overhead, payroll, taxes, and interest of 3.1 K.
Nanobac Pharmaceuticals Incorporated currently holds about 3.93 K in cash with (910.89 K) of positive cash flow from operations.
Nanobac Pharmaceuticals has a very weak financial position based on the latest SEC disclosures

Nanobac Pharmaceuticals Technical Analysis

Nanobac Pharmaceuticals' future price can be derived by breaking down and analyzing its technical indicators over time. Nanobac Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Nanobac Pharmaceuticals Incorporated. In general, you should focus on analyzing Nanobac Stock price patterns and their correlations with different microeconomic environments and drivers.

Nanobac Pharmaceuticals Predictive Forecast Models

Nanobac Pharmaceuticals' time-series forecasting models is one of many Nanobac Pharmaceuticals' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Nanobac Pharmaceuticals' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

Things to note about Nanobac Pharmaceuticals

Checking the ongoing alerts about Nanobac Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Nanobac Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Nanobac Pharmaceuticals generated a negative expected return over the last 90 days
Nanobac Pharmaceuticals has some characteristics of a very speculative penny stock
Nanobac Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years
The company reported the previous year's revenue of 17.62 K. Net Loss for the year was (6.58 M) with profit before overhead, payroll, taxes, and interest of 3.1 K.
Nanobac Pharmaceuticals Incorporated currently holds about 3.93 K in cash with (910.89 K) of positive cash flow from operations.
Nanobac Pharmaceuticals has a very weak financial position based on the latest SEC disclosures

Additional Tools for Nanobac Stock Analysis

When running Nanobac Pharmaceuticals' price analysis, check to measure Nanobac Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nanobac Pharmaceuticals is operating at the current time. Most of Nanobac Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Nanobac Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nanobac Pharmaceuticals' price. Additionally, you may evaluate how the addition of Nanobac Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.